Ampio Pharmaceuticals, Inc.

As of August 2, 2016, Ampio Pharmaceuticals, Inc. is considered overvalued and does not qualify for a favorable valuation grade due to poor financial metrics, including a P/E ratio of -0.0003 and a one-year return of -97.92%, significantly underperforming against the S&P 500.

As of June 17, 2025, Ampio Pharmaceuticals shows a mildly bullish trend supported by short-term indicators, but caution is advised due to mixed signals from longer-term metrics.

As of March 2022, the management team of Ampio Pharmaceuticals, Inc. includes Mr. Michael Macaluso as Chairman and CEO, with Dr. David Bar-Or as a Director and Mr. Philip Coelho, Mr. Richard Giles, and Dr. David Stevens serving as Independent Directors.

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for inflammatory conditions. As of December 2023, it has a market cap of $0 million and reported a net profit loss of $2 million.

As of Jun 18, Ampio Pharmaceuticals, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -8.63 million over the latest four quarters. Shareholder's funds are 3.36 million, and total assets are 5.74 million.